Medische Oncologie Nummer 8, pp. 17-18
okt 2019, jaargang 22
Medische Oncologie Nr. 8, pp. 17-18
okt 2019, jr. 22
Beleid

NVMO-CONSENSUS COLORECTAAL CARCINOOM NOG GROTENDEELS ACTUEEL ‘Het wachten is op goedkeuring van immuuntherapie’

De NVMO-consensus indicaties oncologische middelen uit 2016 is voor colorectaal carcinoom nog grotendeels actueel. Alleen de patiëntenselectie voor sommige indicaties is ietwat aangescherpt. ‘We zitten wel met smart te wachten op goedkeuring voor het gebruik van immuuntherapie bij patiënten met gemetastaseerde ziekte die een MSI-tumor hebben’, zegt internistoncoloog prof. dr. Kees Punt (Amsterdam UMC, locatie AMC).

‘Het is goed dat er een tweede NVMO-commissie is die zich richt op offlabel-gebruik van geregistreerde middelen’

Referenties:

  1. Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378(13):1177-88.
  2. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a metaanalysis. Eur J Cancer. 2015;51(5):587-94.
  3. Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017;28(8):1713-29.
  4. Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 2017;317(23):2392-401.
  5. Giantonio BJ. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
  6. Cremolini C, Antoniotti C, Lonardi S, et al. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the firstand second-line treatment of unresectable mCRC. Presented at ASCO 2019; Chicago, IL. Abstract 3508.
  7. Kwakman JJ, Baars A, Boot H, et al. Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndromerelated discontinuation of capecitabine in western cancer patients. Acta Oncol. 2017;56(7):1023-6.
  8. Kwakman JJ, Baars A, Van Zweeden AA, et al. Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm. Eur J Cancer. 2017; 81:130-34.
  9. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015;372(20):1909-19.
  10. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med 2015;372(26):2509-20.
  11. Overman MJ, Lonardi S, Wong KY, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instabilityhigh metastatic colorectal cancer. J Clin Oncol. 2018;36:773-9.
Beleid

NVMO-CONSENSUS COLORECTAAL CARCINOOM NOG GROTENDEELS ACTUEEL ‘Het wachten is op goedkeuring van immuuntherapie’

De NVMO-consensus indicaties oncologische middelen uit 2016 is voor colorectaal carcinoom nog grotendeels actueel. Alleen de patiëntenselectie voor sommige indicaties is ietwat aangescherpt. ‘We zitten wel met smart te wachten op goedkeuring voor het gebruik van immuuntherapie bij patiënten met gemetastaseerde ziekte die een MSI-tumor hebben’, zegt internistoncoloog prof. dr. Kees Punt (Amsterdam UMC, locatie AMC).

‘Het is goed dat er een tweede NVMO-commissie is die zich richt op offlabel-gebruik van geregistreerde middelen’

Referenties:

  1. Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378(13):1177-88.
  2. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a metaanalysis. Eur J Cancer. 2015;51(5):587-94.
  3. Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017;28(8):1713-29.
  4. Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 2017;317(23):2392-401.
  5. Giantonio BJ. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
  6. Cremolini C, Antoniotti C, Lonardi S, et al. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the firstand second-line treatment of unresectable mCRC. Presented at ASCO 2019; Chicago, IL. Abstract 3508.
  7. Kwakman JJ, Baars A, Boot H, et al. Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndromerelated discontinuation of capecitabine in western cancer patients. Acta Oncol. 2017;56(7):1023-6.
  8. Kwakman JJ, Baars A, Van Zweeden AA, et al. Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm. Eur J Cancer. 2017; 81:130-34.
  9. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015;372(20):1909-19.
  10. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med 2015;372(26):2509-20.
  11. Overman MJ, Lonardi S, Wong KY, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instabilityhigh metastatic colorectal cancer. J Clin Oncol. 2018;36:773-9.
Over dit artikel
Auteur
Marten Dooper
Over de auteur

Dr. Marten Dooper, wetenschapsjournalist

Printdatum
22 oktober 2019
E-pubdatum
25 oktober 2019
ISSN print
1388-2295
ISSN online
2405-4763


Over dit artikel
Auteur
Marten Dooper
Over de auteur

Dr. Marten Dooper, wetenschapsjournalist

Printdatum
22 oktober 2019
E-pubdatum
25 oktober 2019
ISSN print
1388-2295
ISSN online
2405-4763